CCL2 and Hepatic fibrosis: Notably, a dual inhibitor of CCR2/CCR5, known as Cenicriviroc (CVC), effectively blocks CCL2-mediated monocyte recruitment to the liver and exhibits anti-fibrotic effects in a mouse model of liver fibrosis (167).